VIBRAMYCIN (doxycycline calcium) by Pfizer is mechanism of action mechanism of action doxycycline inhibits bacterial protein synthesis by binding to the 30s ribosomal subunit. Approved for the following infections: rocky mountain spotted fever, typhus fever, the typhus group and 9 more indications. First approved in 1974.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
VIBRAMYCIN (doxycycline calcium) is a broad-spectrum tetracycline antibiotic approved since 1974 that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It treats rickettsial infections (Rocky Mountain spotted fever, typhus, Q fever), gram-negative and gram-positive bacterial infections, and is used for malaria prophylaxis in travelers to resistant-strain areas. The drug has bacteriostatic activity against a wide range of gram-positive and gram-negative organisms.
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting potential team restructuring and transition focus toward generic optimization or combination strategies.
Mechanism of Action Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Resistance Cross resistance with other tetracyclines is…
Worked on VIBRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VIBRAMYCIN represents a mature product management role with emphasis on defensive positioning and margin protection rather than growth or innovation. Pfizer team members are likely focused on cost management, generic transition planning, and specialist prescriber engagement in infectious disease.